Preece Paul, Virley David J, Costandi Moheb, Coombes Robert, Moss Stephen J, Mudge Anne W, Jazin Elena, Cairns Nigel J
Seixo Branco, Departamento de Neurologia, Rua das Brañas 7-bajo-D, Mera, 15177 Oleiros, La Coruña, Galicia, Spain.
Brain Res Mol Brain Res. 2004 Mar 17;122(1):1-9. doi: 10.1016/j.molbrainres.2003.08.022.
Insoluble beta-amyloid deposits in Alzheimer's disease (AD) brain are proteolytically derived from the membrane bound amyloid precursor protein (APP). The APP gene is differentially spliced to produce isoforms that can be classified into those containing a Kunitz-type serine protease inhibitor domain (K(+), APP(751), APP(770), APRP(365) and APRP(563)), and those without (K(-), APP(695) and APP(714)). Given the hypothesis that Abeta is a result of aberrant catabolism of APP, differential expression of mRNA isoforms containing protease inhibitors might play an active role in the pathology of AD. We took 513 cerebral cortex samples from 90 AD and 81 control brains and quantified the mRNA isoforms of APP with TaqMan real-time RT-PCR. After adjustment for age at death, brain pH and gender we found a change in the ratio of KPI(+) to KPI(-) mRNA isoforms of APP. Three separate probes, designed to recognise only KPI(+) mRNA species, gave increases of between 28% and 50% in AD brains relative to controls (p=0.002). There was no change in the mRNA levels of KPI-(APP 695) (p=0.898). Therefore, whilst KPI-mRNA levels remained stable the KPI(+) species increased specifically in the AD brains.
阿尔茨海默病(AD)大脑中不溶性β-淀粉样蛋白沉积物是通过蛋白水解作用从膜结合淀粉样前体蛋白(APP)衍生而来的。APP基因存在差异剪接,产生的异构体可分为含有Kunitz型丝氨酸蛋白酶抑制剂结构域的(K(+)、APP(751)、APP(770)、APRP(365)和APRP(563))以及不含该结构域的(K(-)、APP(695)和APP(714))。鉴于β-淀粉样蛋白(Aβ)是APP异常分解代谢的结果这一假说,含有蛋白酶抑制剂的mRNA异构体的差异表达可能在AD的病理过程中发挥积极作用。我们从90例AD患者和81例对照者的大脑中采集了513份大脑皮质样本,并用TaqMan实时逆转录-聚合酶链反应(RT-PCR)对APP的mRNA异构体进行定量分析。在校正死亡年龄、脑pH值和性别后,我们发现APP的KPI(+)与KPI(-) mRNA异构体的比例发生了变化。设计用于仅识别KPI(+) mRNA种类的三种不同探针显示,AD大脑中相对于对照组增加了28%至50%(p = 0.002)。KPI-(APP 695)的mRNA水平没有变化(p = 0.898)。因此,虽然KPI-mRNA水平保持稳定,但KPI(+)种类在AD大脑中特异性增加。